{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:12:51Z","timestamp":1791882771065,"version":"4.3.4"},"reference-count":72,"publisher":"American Society for Clinical Investigation","issue":"5","funder":[{"name":"Primary Immune Deficiency Treatment Consortium","award":["Primary Immune Deficiency Treatment Grant"],"award-info":[{"award-number":["Primary Immune Deficiency Treatment Grant"]}]},{"DOI":"10.13039\/100012280","name":"Rare Disease Foundation","doi-asserted-by":"crossref","award":["Microgrant"],"award-info":[{"award-number":["Microgrant"]}],"id":[{"id":"10.13039\/100012280","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["AI137183"],"award-info":[{"award-number":["AI137183"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["AI061093"],"award-info":[{"award-number":["AI061093"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2015-06486"],"award-info":[{"award-number":["2015-06486"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,7]]},"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND.<\/jats:bold>\n                    Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency and is frequently complicated by interstitial lung disease (ILD) for which etiology is unknown and therapy inadequate.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>METHODS.<\/jats:bold>\n                    Medical record review implicated B cell dysregulation in CVID ILD progression. This was further studied in blood and lung samples using culture, cytometry, ELISA, and histology. Eleven CVID ILD patients were treated with rituximab and followed for 18 months.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS.<\/jats:bold>\n                    Serum IgM increased in conjunction with ILD progression, a finding that reflected the extent of IgM production within B cell follicles in lung parenchyma. Targeting these pulmonary B cell follicles with rituximab ameliorated CVID ILD, but disease recurred in association with IgM elevation. Searching for a stimulus of this pulmonary B cell hyperplasia, we found B cell\u2013activating factor (BAFF) increased in blood and lungs of progressive and post-rituximab CVID ILD patients and detected elevation of BAFF-producing monocytes in progressive ILD. This elevated BAFF interacts with naive B cells, as they are the predominant subset in progressive CVID ILD, expressing BAFF receptor (BAFF-R) within pulmonary B cell follicles and blood to promote Bcl-2 expression. Antiapoptotic Bcl-2 was linked with exclusion of apoptosis from B cell follicles in CVID ILD and increased survival of naive CVID B cells cultured with BAFF.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSION.<\/jats:bold>\n                    CVID ILD is driven by pulmonary B cell hyperplasia that is reflected by serum IgM elevation, ameliorated by rituximab, and bolstered by elevated BAFF-mediated apoptosis resistance via BAFF-R.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>FUNDING.<\/jats:bold>\n                    NIH, Primary Immune Deficiency Treatment Consortium, and Rare Disease Foundation.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.122728","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T11:02:59Z","timestamp":1551870179000},"source":"Crossref","is-referenced-by-count":85,"title":["BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency"],"prefix":"10.1172","volume":"4","author":[{"given":"Paul J.","family":"Maglione","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Gyimesi","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Cols","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Radigan","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibin M.","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Weinberger","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Lee","sequence":"additional","affiliation":[{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie K.","family":"Grasset","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"},{"name":"Experimental Cardiovascular Medicine, Center for Molecular Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeeb H.","family":"Rahman","sequence":"additional","affiliation":[{"name":"Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cerutti","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"},{"name":"Program for Inflammatory and Cardiovascular Disorders, Institut Hospital del Mar d\u2019Investigacions M\u00e8diques (IMIM), Barcelona, Spain."},{"name":"Catalan Institute for Research and Advanced Studies (ICREA), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham-Rundles","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.03.025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1544"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.8.5498"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12947"},{"key":"B5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/asheducation.V2012.1.301.3798316","article-title":"The many faces of common variable immunodeficiency","volume":"2012","author":"Cunningham-Rundles","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124545"},{"issue":"7","key":"B7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0404-8"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1053\/j.sult.2013.05.002"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.05.057"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2014.04.024"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1325156"},{"issue":"5","key":"B13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.5858\/134.5.691","article-title":"Update on nonneoplastic pulmonary lymphoproliferative disorders and related entities","volume":"134","author":"Guinee","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.08.005"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00202-7"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-602763"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-016-0597-6"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.08.022"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01679.x"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri2572"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2007.04.012"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0047-y"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0107OC"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201501-0103OC"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.07.004"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00220","article-title":"Genetic diagnosis using whole exome sequencing in common variable immunodeficiency","volume":"7","author":"Maffucci","year":"2016","journal-title":"Front Immunol"},{"issue":"10","key":"B30","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.11.002"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.03.005"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074893"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.013"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.041"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/ni829"},{"issue":"2","key":"B37","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4049\/jimmunol.159.2.794","article-title":"Interferons up-regulate STAT1, STAT2, and IRF family transcription factor gene expression in human peripheral blood mononuclear cells and macrophages","volume":"159","author":"Lehtonen","year":"1997","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.02.004"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1914"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901984106"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2771"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"B43","first-page":"1077","article-title":"Rituximab therapy in primary Sj\u00f6gren\u2019s syndrome with interstitial lung disease: a retrospective cohort study","volume":"34","author":"Chen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex072"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9755-3"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200402000-00014"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155218"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.523"},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-206859","article-title":"Azathioprine-induced hepatitis and cholestasis occurring 1\u2005year after treatment","author":"Chertoff","year":"2014","journal-title":"BMJ Case Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121110"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610528"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu369"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.11.013"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.03.001"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315625119"},{"issue":"12","key":"B56","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140039"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2994"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-014-0068-6"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3175"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2017.72"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ng1600"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.10.001"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69854"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00025-6"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0538-x"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22625"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks042"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.4295"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nri3158"},{"key":"B72","doi-asserted-by":"crossref","DOI":"10.1038\/srep20686","article-title":"Standardizing flow cytometry immunophenotyping analysis from the Human ImmunoPhenotyping Consortium","volume":"6","author":"Finak","year":"2016","journal-title":"Sci Rep"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/122728\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:32:51Z","timestamp":1779193971000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/122728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3,7]]},"published-print":{"date-parts":[[2019,3,7]]}},"alternative-id":["10.1172\/jci.insight.122728"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.122728","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"article-number":"e122728"}}